ReproCELL Incorporated

4978

JP3974770004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
139 ^JPY	-2.11%		0.00%	-20.57%

2023	ReproCELL Incorporated announced that it has received ¥5.3 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	CI
2023	ReproCELL Incorporated announced that it expects to receive ¥5.3 million in funding	CI

ReproCELL, Inc. announced that it has received ¥6.79 million in funding from Evolution Capital Management, LLC

June 10, 2018

On June 11, 2018, ReproCELL, Inc. (JASDAQ:4978) closed the transaction.

Latest news about ReproCELL Incorporated

ReproCELL Incorporated announced that it has received ¥5.3 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	Dec. 20	CI
ReproCELL Incorporated announced that it expects to receive ¥5.3 million in funding	Dec. 04	CI
ReproCELL Incorporated Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Histocell, S.L. announced that it expects to receive ?0.4 million in funding from ReproCELL Incorporated	22-11-07	CI
REPROCELL Signs Agreement to Prospectively Collect Samples for IFF's Microbiome Study	22-04-20	CI
Hoth Therapeutics Extends Partnership Agreement with REPROCELL	21-10-19	CI
Steminent Biotherapeutics, Inc announced that it expects to receive $0.8 million in funding from ReproCELL Incorporated	21-10-11	CI
Reprocell Signs Strategic Collaboration Agreement with TEXCELL to Boost Its GMP iPSC	21-09-01	CI
Curato Japan Co., Ltd. agreed to acquire unknown stake in Repro Curato Co., Ltd. from ReproCELL Incorporated.	21-07-15	CI
ReproCELL Incorporated announced that it has received ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm	21-06-16	CI
ReproCELL Incorporated announced that it expects to receive ¥17.69 million in funding from SMBC Nikko Securities Inc., Investment Arm	21-05-31	CI
Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs	19-10-29	CI
Neucyte, Inc and Reprocell Enters into Distribution Partnership	19-09-25	CI
ReproCELL Incorporated acquired the remaining 0.87% stake in BioServe Biotechnologies Pvt Ltd. for INR 0.85 million.	19-07-09	CI
ReproCELL, Inc. announced that it has received ¥6.79 million in funding from Evolution Capital Management, LLC	18-06-10	CI
ReproCELL, Inc. announced that it expects to receive ¥6.79 million in funding from Evolution Capital Management, LLC	18-05-24	CI
ReproCELL, Inc. completed the acquisition of 98.28% stake in BioServe Biotechnologies Pvt Ltd from Cancer Genetics, Inc..	18-04-26	CI
ReproCELL, Inc. concluded a contract to acquire 98.28% stake in BioServe Biotechnologies Pvt Ltd from Cancer Genetics, Inc. for $1.9 million.	18-04-25	CI
Q Therapeutics, Inc. Announces Joint Venture With ReproCELL, Inc	18-04-23	CI
Q Therapeutics, Inc. Announces Research Collaboration with REPROCELL Inc	17-12-13	CI
BioServe Biotechnologies, Ltd. cancelled the acquisition of Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc..	17-07-31	CI
ReproCELL, Inc. announced that it has received ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	16-12-18	CI
Kringle Pharma, Inc. announced that it has received ¥610 million in funding from a group of investors	16-12-04	CI
ReproCELL, Inc. announced that it expects to receive ¥15.86 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	16-12-01	CI
BioServe Biotechnologies, Ltd. agreed to acquire Stemgent Inc. and Biopta Inc. from Biopta Ltd and ReproCELL, Inc..	16-07-31	CI

ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for ReproCELL Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REPROCELL INCORPORATED	-20.57%	80.14M
CSL LIMITED	-3.93%	86.16B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.17B
BIOGEN INC.	-16.48%	31.47B
UCB	+54.56%	25.24B
BIOMARIN PHARMACEUTICAL INC.	-13.58%	15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.79%	8.84B
INNOVENT BIOLOGICS, INC.	-2.11%	7.93B

Biopharmaceuticals

ReproCELL Incorporated

Equities

4978

JP3974770004

Pharmaceuticals

ReproCELL, Inc. announced that it has received ¥6.79 million in funding from Evolution Capital Management, LLC

Latest news about ReproCELL Incorporated

Chart ReproCELL Incorporated

Company Profile

Income Statement Evolution

Ratings for ReproCELL Incorporated

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals